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We performed a genome-wide association study for chronic obstructive pulmonary disease (COPD) in three population cohorts, including 2,940 cases and 1,380 controls who were current or former smokers with normal lung function. We identified a new susceptibility locus at 4q22.1 in FAM13A and replicated this association in one case-control group (n = 1,006) and two family-based cohorts (n = 3,808) (rs7671167, combined P = 1.2 × 10 −11 , combined odds ratio in case-control studies 0.76, 95% confidence interval 0.69-0.83).
COPD is characterized by a reduction in lung function with airflow obstruction that is not fully reversible 1 . COPD is the fourth leading cause of mortality in the United States; however, COPD remains under-recognized and underdiagnosed. Although the major risk factor for COPD is cigarette smoking, the development of COPD among current and former smokers is highly variable, and evidence suggests that genetic factors influence the risk of developing COPD 2 . A variety of approaches-including candidate-gene association studies, linkage analysis and rare-variant studies-have been used to search for COPD susceptibility loci, but with the exception of a relatively rare monogenic disorder that can lead to COPD (alpha-1 antitrypsin deficiency), few have been consistently replicated 2 .
Recently, a genome-wide association study (GWAS) for COPD in a cohort from Norway 3 found an association with SNPs at the CHRNA3-CHRNA5-IREB2 locus that replicated in several populations, including individuals with COPD (cases) from the National Emphysema Treatment Trial (NETT) 4 and unaffected individuals (controls) from the Normative Aging Study (NAS) 5 . A second locus near HHIP did not reach genome-wide significance but replicated in a population-based genome-wide association study of the ratio of forced expiratory volume in 1 s (FEV 1 ) to forced vital capacity (FVC) and is likely to represent another COPD susceptibility locus 3, 6 ; the FEV 1 /FVC ratio is a measure of lung function that is part of the diagnostic criteria for COPD. We combined these datasets to form a larger GWAS to search for additional common variants that contribute to COPD susceptibility. Our study included individuals from three populations: (i) the case-control population from Norway 3 , (ii) NETT cases and NAS controls 4,5 and (iii) cases and controls from the multicenter Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study 7 (Supplementary Methods). All of our controls were current or former smokers with normal lung function, and all of our cases with COPD had moderate to very severe disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification 1 . We applied a uniform set of quality-control procedures to each of the three raw Illumina datasets (Supplementary Methods and Supplementary Fig. 1 ) and merged the cleaned data into one primary dataset.
A total of 499,578 markers that passed quality-control criteria in this primary dataset were tested for association in 2,940 cases and 1,380 controls ( Supplementary Tables 1 and 2) . We performed logistic regression analysis adjusting for age and pack-years of cigarette smoking (packs smoked per day multiplied by years of smoking), and we adjusted for population substructure using principal components as covariates in the regression analysis. The genomic inflation factor after adjustment was 1.02, indicating minimal residual evidence of stratification ( Supplementary Fig. 2) .
The locus most highly associated to COPD included two SNPs (rs1903003 and rs7671167) in linkage disequilibrium (r 2 = 0.85) at 4q22.1 in the gene FAM13A-( Table 1 , Fig. 1 and Supplementary Fig. 3 ).
To address the possibility of false positive results due to intrastudy heterogeneity, we additionally performed a stratified analysis in all three case-control groups. The results for this association were similar to those from the primary analysis ( Supplementary Table 3 ). In addition, there was no evidence of between-study heterogeneity of effect for the FAM13A SNPs (I 2 = 0).
To replicate these findings, we first genotyped these two FAM13A SNPs, as well as the third most highly associated SNP in this locus, rs2869967 (r 2 = 0.68 with rs7671167), in 502 cases and 504 controls from the COPDGene Study. We then tested these top two (Supplementary Table 2b) . The association with rs7671167 replicated in COPDGene and in ICGN; in EOCOPD, there was a trend toward an effect in the same direction but no significant association (P = 0.11). The lack of significant association in EOCOPD could be due to phenotypic differences (specifically, selection of probands for younger age of onset and greater severity) or to decreased power from analyzing a relatively small number of pedigrees. As testing for a quantitative trait in the family-based studies could have greater power, we tested rs7671167 for association with FEV 1 , a quantitative measurement of lung function and a key measurement of severity of COPD, and found an association in EOCOPD (pre-bronchodilator P = 0.019 and post-bronchodilator P = 0.06) as well as ICGN (pre-bronchodilator P = 5.3 × 10 −5 and post-bronchodilator P = 3.3 × 10 −4 ). For the replication populations alone, the combined P value for association with COPD status was 1.07 × 10 −5 (Fisher's method, χ 2 = 3.02 × 10 −5 ); the combined P value for association to COPD status across all six populations was 1.22 × 10 −11 (Fisher's method, χ 2 =1.16 × 10 −10 ) ( Table 1) .
FAM13A (also known as FAM13A1) has a putative role in signal transduction, and our most statistically significant SNPs lie in an intronic region downstream of a Rho GTPase-activating protein (RhoGAP) domain 8 . Although little is known about FAM13A function, gene expression analyses in cell lines from several tissues (not including the lung) have shown a consistent increase of expression in response to hypoxia 9 . Differences in respiratory epithelial cell expression of FAM13A have been noted during differentiation into pulmonary type II cells in vitro 10 and in individuals with mild as compared to severe cystic fibrosis 11 . Recently, a population-based GWAS of lung function 12 reported association of a variant at the same locus identified here in FAM13A to FEV 1 /FVC (rs2869967, P = 1.57 × 10 −8 ; rs7671167, P = 6.30 × 10 -7 ). Although the association with rs2869967, or another nearby SNP, rs6830970, failed to replicate in a second study of spirometric phenotypes in the general population 13 , our findings suggest that the results of the original study do not represent a false positive and that variants in FAM13A may be important for both variation of FEV 1 /FVC in the general population as well as susceptibility to COPD.
In addition to our findings at FAM13A, one additional locus was significant at a threshold 14 of P = 5 × 10 −7 and a third was just below this threshold in our initial GWAS ( Supplementary Fig. 3 and Supplementary  Table 4a ). Not surprisingly, these two loci were the previously reported loci in CHRNA3-CHRNA5-IREB2 (P = 4.81 × 10 −7 ) and HHIP (P = 8.38 × 10 −7 ) 3, 6, 12, 13 . We genotyped a subset of these SNPs that were not in complete linkage disequilibrium in COPDGene and found nominal significance for replication (P < 0.05) at the CHRNA3-CHRNA5-IREB2 locus (P = 0.012, Supplementary Table 4a ). However, this locus did not show a genome-wide significant association in our stratified analysis of individual cohorts (Supplementary Table 4b) .
The association of diseases such as COPD and lung cancer 15 with the CHRNA3-CHRNA5-IREB2 locus remains of uncertain significance because of the difficulty in resolving whether this genetic association may be related to cigarette smoking behavior rather than directly to COPD. We found that the identified SNPs in FAM13A were not associated with pack-years of cigarette smoking in either cases or controls (Supplementary Note). We also tested for an interaction effect with these SNPs and pack-years of cigarette smoking; there was no statistically significant evidence of interaction in the primary or replication analyses (Supplementary Note).
We report a large genome-wide association study identifying variants in FAM13A associated with COPD. Although the discovery of new genetic susceptibility variants contributes to our understanding of this disease, it is important to note that cigarette smoking remains a greater risk factor than genetic variants. Despite the use of only current smokers or ex-smokers as controls, the effect size of the genetic variants in this study is small in comparison to the estimated effect of smoking (in the primary analysis, for each 10 pack-years of smoking, odds ratio = 1.5, P = 9.3 × 10 −95 ; Supplementary Methods). However, The primary genome-wide meta-analysis includes 2,940 cases and 1,380 controls from three population cohorts. Replication results are shown for the case-control COPDGene and the family-based EOCOPD and ICGN studies. All analyses are adjusted for age and pack-years of cigarette smoking; the primary analysis is also adjusted for population stratification using principal components. Minor allele frequencies are given for each cohort.
a Chromosome:base position, referencing hg18. CI, confidence interval; OR, odds ratio.
the discovery of genetic risk variants, such as those in FAM13A, could contribute to the eventual development of new therapeutic approaches to COPD.
Note: Supplementary information is available on the Nature Genetics website.
